Press release
HIV Drug Market Poised to Reach $41.08 Billion by 2030 with 4.26% CAGR
HIV Drugs Market
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1092
According to the latest research by InsightAce Analytic, the global HIV Drugs market is valued at US$ 29.43 Billion in 2021, and it is expected to reach US$ 41.08 Billion by 2030, with a CAGR of 4.26% during a forecast period of 2022-2030.
One of the most severe and persistent illnesses brought on by the human immunodeficiency virus (HIV) is regarded to be acquired immune deficiency syndrome (AIDS). It is a viral infection that grows through contact with blood, semen, breast milk, and other agents that have HIV infected them. HIV infection rates are increasing dramatically. The World Health Organization (WHO) evaluates that 33.0 million people worldwide are HIV-positive at this time. People are now more and more conscious of this, which has increased the number of testing processes. High potency HIV drugs are now in high demand for the treatment and management of the condition as a result of this.
The demand for HIV drugs has been positively impacted by the increase in HIV disease prevalence around the globe. HIV drugs assist in preventing the HIV virus from replicating, hence lowering the risk of transmission. HIV treatment operations being rescheduled could lead to a future patient backlog. For these conditions, it is possible to advise medication and lifestyle modifications till further notice. Additionally, some private hospitals and clinics treat HIV in nations like the U.S. However, it is recommended that clinics and clients uphold social estrangement standards. Therefore, it is expected that all of these variables will have an impact on the market for HIV drugs in the future.
HIV prevalence and the rate of HIV diagnosis and treatment are the two main reasons driving the market growth for HIV drugs. Additionally, government initiatives to raise public awareness of the causes, signs, and treatments for HIV are intensifying. These initiatives stress the importance of these treatments in halting the spread of the HIV virus. As a result, increased awareness brought on by such government activities is anticipated to fuel the growth of the HIV medicine market. The market for HIV medications is anticipated to develop, although strict government requirements for the approval and commercialization of HIV drugs are projected to impede this.
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02
North America is anticipated to be the major contributor to the HIV Drugs market over the forecast years. The rising prevalence of HIV infection among Americans is to blame for this region's dominance. The Centers for Disease Control (CDC) counted in 2021 that at the end of 2018, about 1.2 million people were living with HIV. Such a large patient group greatly increases the need for HIV medications. The population's awareness is another element influencing the progress of the region. In addition, the Asia Pacific HIV Drugs market is expected to grow significantly during the forecast period due to an increasing elderly population and an expanding population overall.
Major market players operating in the HIV Drugs market include
Gilead Sciences, Janssen, Merck & Co., Bristol-Myers Squibb, TaiMed Biologics, CytoDyn, ViiV Healthcare, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Cipla Limited, AbbVie, F. Hoffmann-La Roche Ltd., Daiichi Sankyo, Emcure, Hetero Drugs, and Mylan among others.
Recent collaborations and agreements in the market:
• In July 2021, Darunavir paired with ritonavir (DRV/r) will be made available as a second-line medication for HIV patients in low and middle-income countries for US$ 210 per patient/year, according to a pricing agreement announced by Unitaid and the Clinton Health Access Initiative, Inc. (CHAI) and Hetero Labs LTD.
• In March 2021, A partnership contract was struck by Merck and Gilead Sciences Inc. to develop and market long-acting HIV treatment jointly. The firms want to combine Merck's investigational nucleoside reverse transcriptase translocation inhibitor islatravir and Gilead's investigational capsid inhibitor lenacapavir to produce a two-drug regimen for HIV.
• In January 2021, ViiV Healthcare created Cabenuva, an injectable drug authorized by the US Food and Drug Administration to treat adult patients with human immunodeficiency virus type 1 (HIV) infections.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1092
Market Segments
Global HIV Drugs Market, by Product, 2022-2030 (Value US$ Bn)
• Zolgensma
• Atripla
• Biktarvy
• Complera
• Delstrigo
• Descovy
• Dovato
• Genvoya
• Isentress
• Juluca
• Odefsey
• Stribild
• Symtuza
• Tivicay
• Triumeq
• Trogarzo
• Truvada
• Cabotegravir/Rilpivirine
• Fostemsavir
• Leronlimab
• Others
Global HIV Drugs Market, by Region, 2022-2030 (Value US$ Bn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America HIV Drugs Market, by Country, 2022-2030 (Value US$ Bn)
• U.S.
• Canada
Europe HIV Drugs Market, by Country, 2022-2030 (Value US$ Bn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific HIV Drugs Market, by Country, 2022-2030 (Value US$ Bn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America HIV Drugs Market, by Country, 2022-2030 (Value US$ Bn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa HIV Drugs Market, by Country, 2022-2030 (Value US$ Bn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa
Why should buy this report:
To receive a comprehensive analysis of the prospects for the global HIV Drugs market
To receive an industry overview and future trends of the HIV Drugs market
To analyze the HIV Drugs market drivers and challenges
To get information on the HIV Drugs market value (US$Bn) forecast to 2030
Significant investments, mergers & acquisitions in the HIV Drugs market industry
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release HIV Drug Market Poised to Reach $41.08 Billion by 2030 with 4.26% CAGR here
News-ID: 3891650 • Views: …
More Releases from Insightace Analytic Pvt Ltd.
Prochlorperazine Maleate Market Size, Share and Trends Analysis Report 2025-2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Prochlorperazine Maleate Market- (By Indication (Nausea and Vomiting Management, Vertigo, Mental Health Disorders (e.g., Schizophrenia)), By Dosage Form (Oral Tablets, Rectal Suppositories, Injectable Formulations), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End-User (Hospitals, Clinics, Ambulatory Surgical Centers, Homecare Settings)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research…
Primary Cells Market Survey Detailed Analysis and Forecast 2025-2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Primary Cells Market- (By Type (Hematopoietic, Dermatocytes, Hepatocytes, Gastrointestinal, Lung, Renal, Heart, Musculoskeletal), Origin (Human Primary Cells, Animal Primary Cells), End User (Life Science Research Companies, Research Institutes, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic, the Global Primary Cells Market Size is valued at USD…
Predictive Disease Analytics Market expected to Witness Huge Revenue Growth to 2 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Predictive Disease Analytics Market Size, Share & Trends Analysis Report By Component (Hardware, Software & Services), By Deployment (On-premise and Cloud-based), By End-user (Healthcare Providers, Healthcare Payers)- Market Outlook And Industry Analysis 2034"
The Global Predictive Disease Analytics Market is estimated to reach over USD 22.6 Bn by 2034, exhibiting a CAGR of 21.2% during…
Predictive Biomarkers Market Current Scenario with Future Trends Analysis to 203 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Predictive Biomarkers Market- (By Indication (Cancer, Neurological Disorder, Cardiovascular Disorder, Immunological Disorder, Others), By End-Use (Diagnostic Centers, Contract Research Organizations (CROs), Academic Research Institutes, Pharma & Biotech Companies, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic, the Global Predictive Biomarkers Market is expected to grow with…
More Releases for HIV
HIV Drugs Market - Defeating HIV Together: Advancing Treatment Options for a Bri …
Newark, New Castle, USA: The "HIV Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
HIV Drugs Market: https://www.growthplusreports.com/report/hiv-drugs-market/7792
This latest report researches the industry structure, sales, revenue,…
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of…
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication…
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments
Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV…
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Introduction to Human Immunodeficiency Virus (HIV) Vaccines
1.1 Overview
1.2 Antiquity of HIV Vaccine
Need for the Development of HIV Vaccine
Primer of HIV inside the Body
3.1 Inclusion of HIV Virus into the System
3.2 Interaction of HIV with Host
3.3 Eradication of HIV Virus
HIV Vaccine Development Process
4.1 Introduction
…
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways…
